IGM BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.4 USD | +22.88% |
|
+30.56% | +13.12% |
| 04-17 | IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets | MT |
| 04-17 | IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration | CI |
| Sales 2024 * | 3.04M 243M | Sales 2025 * | 12.25M 980M | Capitalization | 554M 44.31B |
|---|---|---|---|---|---|
| Net income 2024 * | -200M -15.99B | Net income 2025 * | -222M -17.75B | EV / Sales 2024 * | 127 x |
| Net cash position 2024 * | 168M 13.42B | Net cash position 2025 * | 170M 13.58B | EV / Sales 2025 * | 31.4 x |
| P/E ratio 2024 * |
-2.89
x | P/E ratio 2025 * |
-3.24
x | Employees | 224 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.53% |
More Fundamentals
* Assessed data
More news
Latest transcript on IGM Biosciences, Inc.
More recommendations
More press releases
More news
| 1 day | +22.88% | ||
| 1 week | +30.56% | ||
| Current month | -2.59% | ||
| 1 month | -2.59% | ||
| 3 months | -11.57% | ||
| 6 months | +128.16% | ||
| Current year | +13.12% |
1 week
6.39
9.48
1 month
6.3910.85
Current year
6.3917.70
1 year
3.8117.70
3 years
3.8199.44
5 years
3.81133.00
10 years
3.81133.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 31/01/03 |
Misbah Tahir
DFI | Director of Finance/CFO | 49 | 31/12/18 |
T. S. Harigopal
COO | Chief Operating Officer | - | 31/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 25/01/21 |
M. Wilsey
BRD | Director/Board Member | 71 | 30/01/19 |
Fred Schwarzer
CEO | Chief Executive Officer | 72 | 31/01/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% | ||
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 9.4 | +22.88% | 468,943 |
| 25/04/24 | 7.65 | -3.89% | 546,460 |
| 24/04/24 | 7.96 | +3.38% | 693,446 |
| 23/04/24 | 7.7 | +14.07% | 413,520 |
| 22/04/24 | 6.75 | -6.25% | 238,720 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Companyâs pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Companyâs development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
9.4
USD
Average target price
21.6
USD
Spread / Average Target
+129.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.12% | 554M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IGMS Stock
